

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY**

HORIZON PHARMA IRELAND LIMITED,
HZNP LIMITED and HORIZON PHARMA
USA, INC.,

Plaintiffs,

v.

ACTAVIS LABORATORIES UT, INC.,

Defendant.

Civil Action No. 14-7992-NLH-AMD
(Consolidated with C.A. Nos. 15-5025, 15-
6131, and 15-6989)

Hon. Noel L. Hillman, U.S.D.J.

Hon. Ann Marie Donio, U.S.M.J.

Document Electronically Filed

**STIPULATION AND ORDER MODIFYING THE
DISCOVERY CONFIDENTIALITY ORDER ENTERED JUNE 1, 2015**

Whereas, on June 1, 2015, the Court entered a stipulated Discovery Confidentiality Order (Dkt. 35) in the above-captioned litigation involving Plaintiffs Horizon Pharma Ireland Limited, HZNP Limited and Horizon Pharma USA, Inc. (collectively, “Horizon”) and Defendant Actavis Laboratories UT, Inc. (“Actavis”);

Whereas several additional related actions have been filed by Horizon against other defendants, which involve some or all of the same patents as those at issue in the above-captioned litigation against Actavis;

Whereas discovery confidentiality orders previously have been entered in many of the related actions and are being negotiated in the remaining actions;

Whereas Actavis believes modification of the Discovery Confidentiality Order (Dkt. 35) is appropriate to facilitate coordination between Actavis and certain defendants in the related actions while ensuring the preservation of the parties’ confidential information;

Whereas Horizon does not oppose modification of the Discovery Confidentiality Order (Dkt. 35) to permit an exchange of certain Horizon information among the defendants in related actions;

NOW THEREFORE, Horizon and Actavis, by and through their respective undersigned counsel in the Action, and subject to the approval of the Court, stipulate and agree to modify the Discovery Confidentiality Order (Dkt. 35) to add the provision below:

21. RELATED ACTIONS

Horizon will be producing CONFIDENTIAL INFORMATION or HIGHLY CONFIDENTIAL INFORMATION to each defendant in *Horizon Pharma Ireland Ltd. v. Actavis Laboratories UT, Inc.*, No. 1:14-cv-7992 (D.N.J.) (consolidated), *Horizon Pharma Ireland Ltd. v. Lupin Ltd. et al.*, No. 1:15-cv-3051 (D.N.J.), *Horizon Pharma Ireland Ltd. et al. v. Amneal Pharmaceuticals LLC*, No. 1:15-cv3367 (D.N.J.) (consolidated), *Horizon Pharma Ireland Ltd. et al. v. Amneal Pharmaceuticals LLC*, No. 1:15-cv-6990 (D.N.J.), and *Horizon Pharma Ireland Ltd. v. IGI Labs.*, No. 1:15-cv-3508 (D.N.J.) (consolidated) (“Related Actions”). Defendants in the Related Actions who are bound by a Discovery Confidentiality Order (“DCO”) entered by this Court in any of the Related Actions may exchange documents designated as containing Horizon CONFIDENTIAL INFORMATION or HIGHLY CONFIDENTIAL INFORMATION so long as every defendant who receives the documents is bound by a DCO entered by this Court in any of the Related Actions and treats all designated materials in accordance with that DCO. The exchange contemplated by this paragraph does not modify any of the restrictions on the dissemination of Horizon CONFIDENTIAL INFORMATION or HIGHLY CONFIDENTIAL INFORMATION set forth in the DCOs entered in each Related Action.

Horizon may not produce or otherwise disclose Actavis's CONFIDENTIAL INFORMATION or HIGHLY CONFIDENTIAL INFORMATION to another defendant in one of the Related Actions or use Actavis's CONFIDENTIAL INFORMATION or HIGHLY CONFIDENTIAL INFORMATION in one of the Related Actions absent (a) consent of the Producing Party or (b) an Order from the Court.

AGREED AND STIPULATED TO:

March 4, 2016

By: s/ John E. Flaherty

John E. Flaherty
Ravin Patel
McCARTER & ENGLISH
Four Gateway Center
100 Mulberry St.
Newark, NJ 07102
(973) 622-4444

Of Counsel:

Robert F. Green
Christopher T. Griffith
Caryn C. Borg-Breen
Jessica M. Tyrus
Benjamin D. Witte
GREEN GRIFFITH & BORG-BREEN LLP
455 North Cityfront Plaza Drive
Suite 3100
Chicago, Illinois 60611
(312) 883-8000

Dennis A. Bennett
GLOBAL PATENT GROUP, LLC
1005 North Warson Road, Suite 404
St. Louis, Missouri 63132
(314) 812-8020

*Attorneys for Plaintiffs Horizon Pharma
Ireland Limited, HZNP Limited and Horizon
Pharma USA, Inc.*

By: s/Liza M. Walsh

Liza M. Walsh
Christine I. Gannon
Christopher J. Borchert
CONNELL FOLEY LLP
One Newark Center
1085 Raymond Boulevard, 19th Floor
Newark, New Jersey 07102
Phone: (973) 757-1100
Fax: (973) 757-1090

Of Counsel:

Ralph J. Gabric
Laura A. Lydigsen
Joshua E. Ney, Ph.D.
Joshua H. James
Andrew McElligott
BRINKS GILSON & LIONE
455 North Cityfront Plaza Drive
Suite 3600
Chicago, Illinois 60611-5599
(312) 321-4200

*Attorneys for Defendant Actavis
Laboratories UT, Inc.*

It is SO ORDERED, this _____ day of March, 2016.

THE HONORABLE ANN MARIE DONIO
UNITED STATES MAGISTRATE JUDGE